Dr. Scott May, PhDEli Lilly and Company における VP of Chemistry, Synthetic Molecule Design & Developmentスピーカー
プロフィール
Scott May, Ph.D., is VP of Chemistry in Synthetic Molecule Design and Development (SMDD) at Eli Lilly and Company. He earned a B.S. in Chemistry from Hope College and a Ph.D. from Indiana University. Scott has led Lilly's efforts in Continuous Manufacturing and Oligonucleotide Synthesis, which have resulted in new facilities within development, manufacturing, and at external partners. His recent work focuses on transforming the synthesis of oligonucleotide therapeutics to reduce costs, minimize environmental impact, and improve patient access to advanced medicines in Lilly's portfolio.
アジェンダセッション
Emerging Technologies in the Scale Up of Oligonucleotide Therapeutics
, 4:00pmセッションを見るDevelopment and Manufacture of Oligonucleotides via Enzymatic Ligation
, 3:45pmセッションを見る